University of Utah

CBRE named Salt Lake City an emerging life sciences market due to the city’s incentive programs, talent pools and manageable cost of living.\n Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while also establishing a venture fund to support early-stage life sciences and biotech companies.The expansion is part of Portal’s managed services platform, Powered by Portal, which has launched incubator locations in Chicago, New Jersey and Rhode Island over the past two years. The Utah location is scheduled to open in the second quarter of 2027, according to a March 5 announcement.The facility will include wet- and dry-lab space designed to help commercialize academic research through venture-backed companies, offering founder support and early-stage investment, according to the VC firm. The Utah incubator, called Woodbine Labs, Powered by Portal, will receive support from trade organization BioUtah and serve as a launchpad for research emerging from the University of Utah and Brigham Young University.Member companies will also gain access to Chicago-based Portal’s private network platform, which connects entrepreneurs, operators, investors and strategic partners to improve access to capital and expertise, Portal Innovations said. The nationwide network has supported 150 companies and more than 500 members.The new venture fund, meanwhile, will invest in high-potential companies emerging from the incubator—with Convexity Properties and High Boy Ventures backing it.“Utah has all the ingredients for continued life sciences and techbio growth, especially at the interface between AI and biology, and we’re excited to be part of that momentum in Salt Lake City,” Portal Innovations founder and CEO John Flavin said in the release.Portal’s Utah investment builds on several recent biotech developments in Salt Lake City, which commercial real estate firm CBRE named an emerging life sciences market in a 2025 report. CBRE cited the city’s incentive programs, its top-10 medtech talent pool, its 17th-ranked biopharma workforce and its lower cost of living as key drivers of biotech industry growth.Last year, Ratio Therapeutics signed a deal to build a 65,000-square-foot manufacturing facility in the city to expand its capacity to produce radiopharmaceutical treatments and diagnostics. The facility is expected to open in the second half of 2027.

SALT LAKE CITY, Feb. 26, 2026 /PRNewswire/ -- ARUP Laboratories, a leader in diagnostic medicine and the largest nonprofit reference laboratory in the U.S., today announced the launch of a new Innovation Central Laboratory to facilitate collaboration with pharmaceutical, biotechnology, and other industry partners. The Innovation Central Laboratory will serve as an ecosystem for validating technologies and accelerating next generation diagnostics from concept to commercialization. Continue Reading Leaders of ARUP’s Innovation Business Unit discuss their latest developments. Pictured from left to right are Hunter Best, PhD, FACMG; Tracy George, MD; Erica Clyde, MBA, PMI-PMP®, MB(ASCP)CM; and Salika Shakir, PhD, D(ABMM). "The Innovation Central Laboratory represents a bold step forward in diagnostic medicine," said Tracy George, MD, ARUP chief scientific officer and president of ARUP's Innovation Business Unit. "By building and validating tests that are truly commercial-ready, we're not just accelerating innovation, we're ensuring that groundbreaking diagnostics can be adopted in real-world laboratories to improve patient care globally." Drawing from ARUP's deep clinical, scientific, and regulatory expertise and experience, the Innovation Central Laboratory provides an opportunity for biotechnology and pharmaceutical partners to collaborate with ARUP on early-stage exploration and refinement of novel diagnostic concepts outside of routine clinical workflows. ARUP offers a full suite of services and full life cycle management to help partners accelerate innovation and get products to market efficiently and effectively. The launch of the Innovation Central Laboratory is the latest in a series of innovative developments from ARUP. In April 2025, ARUP launched a blood-based biomarker assay to determine whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer's disease (AD) pathology. Blood-based biomarkers provide a more accessible and less invasive diagnostic tool than standard methods, such as amyloid positron emission tomography imaging, and may facilitate earlier detection of AD. ARUP has also partnered with Tasso Inc. to develop at-home blood testing services that will support clinical research. ARUP has already validated several assays using capillary blood microsamples, which are collected using the Tasso device, and will serve as the performing laboratory of the combined service. The new partnership with Tasso is an additional element of ARUP's robust offerings to support clinical trials. ARUP's central pathology review service has also played a pivotal role in supporting clinical trials, including a promising therapy for patients with nonadvanced systemic mastocytosis. Other current initiatives of the ARUP Central Innovation Laboratory include developing assays for rare and underrecognized diseases, improving genomic sequencing technologies, operationalizing artificial intelligence (AI) and digital pathology solutions into laboratory workflows, and facilitating biomarker discovery and development of new assays for neurodegenerative diseases. Learn more about the ARUP Central Innovation Laboratory and the ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ here. About ARUP Innovation Central Laboratory Pharmaceutical, biotechnology, and industry partners are invited to collaborate with ARUP through the Central Innovation Laboratory to bring next generation diagnostics from concept to commercialization. ARUP offers comprehensive services to support innovative healthcare solutions for industry partners, including custom assay development, clinical trial support, central pathology review, applied artificial intelligence and bioinformatics solutions, and more. About ARUP Laboratories Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah Spencer Fox Eccles School of Medicine and its Department of Pathology. ARUP offers more than 3,000 tests and test combinations, ranging from routine screening tests to esoteric molecular and genetic assays. In addition, ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™. ARUP is an ISO 15189- and CAP-accredited laboratory. For more information, visit . Media Contact Kellie Carrigan [email protected] [email protected] SOURCE ARUP Laboratories 21% more press release views with Request a Demo

PHILADELPHIA, Feb. 18, 2026 /PRNewswire/ -- Daymark Health, the company transforming the cancer care experience for patients, providers, and health plans, today announced the formation of its Clinical Advisory Board, a distinguished group of healthcare leaders and experts who will provide strategic guidance and clinical insight as the company delivers on its mission of transforming cancer care. Comprised of a cross-functional group of renowned physicians, researchers, nurses, and innovators, Daymark's Clinical Advisory Board brings diverse experience from fields including oncology, value-based care, and health policy: Cardinale Smith, MD – Dr. Cardinale Smith, Chief Medical Officer at the Memorial Sloan Kettering Cancer Center, is a thoracic medical oncologist and one of the nation's preeminent lung cancer specialists. Dr. Smith is also a renowned expert and research leader in palliative care, community engaged interventions, and managing cancer symptoms and side effects. Ezekiel Emanuel, MD – An oncologist, Vice Provost of Global Initiatives at the University of Pennsylvania, and a key architect of the Affordable Care Act, Dr. Ezekiel Emanuel has been an influential voice in American health policy and reform for many years. He has dedicated years to creating strategies to lower health care costs, strengthen systems, and intervene in public health initiatives. Carol DeVol – As the former Chief Operating Officer and Co-Founder of Landmark, a home-based care services company acquired by Optum in 2021, Carol DeVol has a deep history of success in population health, practice management, and disease management. Ms. DeVol is a career operator with extensive experience managing risk arrangements with vulnerable populations and has implemented over sixty home- based primary care programs in twenty-six states. Jennifer Malin, MD, PhD – An oncologist, former Senior Vice President at Optum, former Chief Medical Officer of Oncology at United Healthcare, and current Chief Medical Officer of Medzown, Dr. Jennifer Malin has over 20 years experience designing and implementing value-based care initiatives in oncology, rare disease, precision medicine and population health for large national payers and health care delivery organizations. She continues to serve as an attending medical oncologist at the U.S. Department of Veteran Affairs. The Honorable David Shulkin, MD – Dr. David Shulkin is a physician and the former United States Secretary of Veterans Affairs, where he represented 21 million American veterans and was responsible for the nation's largest integrated health care system with over 1,200 sites of care. Prior to his years in government service, Dr. Shulkin served as the CEO of several leading hospitals and health systems, including Beth Israel in New York City and Morristown Medical Center in New Jersey. Shelley Fuld Nasso, MPP – Ms. Shelley Fuld Nasso is CEO of Cancer Nation (formerly known as the National Coalition for Cancer Survivorship), where she pushes for bold policy change to ensure every survivor has the right to not just survive, but thrive. From healthcare policy to care delivery, Ms. Fuld Nasso has worked to spotlight survivor voices and advocate for cancer care that actually works for the people living with cancer. Kathi Mooney, PhD, RN – Dr. Kathi Mooney is a Distinguished Professor at the University of Utah College of Nursing. Dr. Mooney is an expert in rural healthcare and has worked across various aspects of the cancer care journey, including symptom management, technology-aided interventions, cancer family caregivers, and improving supportive care outcomes for patients in frontier communities. Roy Beveridge, MD – As a medical oncologist and the former Chief Medical Officer at both Humana and US Oncology, Dr. Roy Beveridge has deep expertise in value-based care generally and oncology practice dynamics specifically. Dr. Beveridge also serves as Daymark's executive board chair. "Daymark has assembled an expert group of clinicians, researchers, and patient advocates with a shared purpose: to completely transform the cancer care experience for patients and the system at large," said Dr. Cardinale Smith, Chief Medical Officer at Memorial Sloan Kettering Cancer Center. "From the hospital to the board room to Capitol Hill, my fellow Board members and I are honored to shape the future of cancer care alongside a company that's driving such meaningful results in patient impact and outcomes." "Living with cancer can mean managing significant symptoms, uncertainty, long wait times, and emotional upheaval," said Shelley Fuld Nasso, MPP, CEO of Cancer Nation. "Daymark is raising the bar for patient-centered care across the cancer journey. I'm excited to collaborate with the Daymark team and fellow Advisory Board members to advocate for patients and elevate their voices." The Clinical Advisory Board will share strategic insight into key areas of Daymark's work, drawing on clinical, operational, and patient perspectives to inform the company's care model and strategy. Members will also support Daymark in forging new partnerships with health plans, provider groups, and additional partners. "As we continue to grow and expand on our mission at Daymark, our Clinical Advisory Board will help ensure that we're building scalable and high-quality solutions that meet the evolving needs of patients, providers, health plans, and other partners," said Dr. Justin Bekelman, Co-Founder and CEO at Daymark Health. "We feel privileged to welcome this accomplished and respected group of experts to Daymark and continue delivering an exceptional, patient-centered cancer care experience." For more information about Daymark Health and its Clinical Advisory Board, visit . About Daymark Health Daymark Health is a cancer care company that partners with health plans to provide in-home and virtual supportive and wraparound care to patients with cancer in collaboration with their own oncologists. Daymark's supportive, personalized cancer care program empowers patients with care navigation, 24/7 support, mental health assistance, symptom management, and social support – all delivered virtually and in the home. For more information, visit . SOURCE Daymark Health 21% more press release views with Request a Demo